BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/5/2014 11:43:00 AM | Browse: 1197 | Download: 1373
Publication Name World Journal of Gastroenterology
Manuscript ID 12064
Country Denmark
Received
2014-06-20 08:51
Peer-Review Started
2014-06-20 20:52
To Make the First Decision
2014-07-09 12:09
Return for Revision
2014-07-17 15:47
Revised
2014-07-28 16:00
Second Decision
2014-09-05 16:49
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2014-09-05 17:18
Articles in Press
2014-09-05 17:28
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2014-11-06 09:42
Publish the Manuscript Online
2014-11-20 20:51
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Topic Highlights
Article Title Risk of infections associated with biological treatment in inflammatory bowel disease
Manuscript Source Invited Manuscript
All Author List Nynne Nyboe Andersen and Tine Jess
Funding Agency and Grant Number
Corresponding Author Nynne Nyboe Andersen, MD, Department of Epidemiology Research, Statens Serum Institut, Artillerivej 5, DK-2300 Copenhagen, Denmark. nyna@ssi.dk
Key Words Inflammatory bowel disease; Biological treatment; Tumor necrosis factor-α inhibitors; Risk; Infections; Ulcerative colitis; Crohn’s disease
Core Tip The use of tumor necrosis factor-α (TNF-α) inhibitors are increasing worldwide for the treatment of several chronic immune-mediated diseases as rheumatoid arthritis and inflammatory bowel disease (IBD). As the drugs are relatively new on the market, their long-term safety profile remains uncertain. In particular, a concern regarding an increased infections risk has been debated. In the current topic highlight, a brief overview of the current literature regarding the risk of infections in patients with IBD exposed to TNF-α inhibitors is outlined.
Publish Date 2014-11-20 20:51
Citation Andersen NN, Jess T. Risk of infections associated with biological treatment in inflammatory bowel disease. World J Gastroenterol 2014; 20(43): 16014-16019
URL http://www.wjgnet.com/1007-9327/full/v20/i43/16014.htm
DOI http://dx.doi.org/10.3748/wjg.v20.i43.16014
Full Article (PDF) WJG-20-16014.pdf
Full Article (Word) WJG-20-16014.doc
Manuscript File 12064-Review.docx
Answering Reviewers 12064-Answering reviewers.pdf
Copyright License Agreement 12064-Copyright assignment.pdf
Peer-review Report 12064-Peer review(s).pdf
Scientific Misconduct Check 12064-CrossCheck.jpg
Scientific Editor Work List 12064-Scientific editor work list.pdf